Literature DB >> 8259216

Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit.

Y Gu1, C W Turck, D O Morgan.   

Abstract

The major events of the cell division cycle are triggered by periodic changes in the activity of cyclin-dependent protein kinases (CDKs). In mammals, the members of the CDK family include CDK2 and CDC2, which are thought to be involved in the control of DNA replication and mitosis, respectively. The protein kinase activity of these enzymes is controlled by a complex array of mechanisms. Activation of the CDK catalytic subunit requires association with a positive regulatory subunit (cyclin) and phosphorylation (at Thr 160 in CDK2). This activated complex can be inhibited by additional phosphorylation at Thr 14 and Tyr 15. Here we report the identification of a new mechanism for the regulation of CDK2 activity. We find that CDK2/cyclin complexes in mouse fibroblasts associate tightly with a 20K protein (CAP20). Complexes containing CAP20 were isolated from cell lysates and found to have negligible kinase activity, indicating that CAP20 association in vivo may inhibit CDK2 activity. We purified CAP20 from 3T3 cells and found that low concentrations of the protein completely inhibit the kinase activity of CDK2 in vitro. Thus CAP20 represents a new negative regulatory subunit that inhibits the activity of CDK2/cyclin complexes in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8259216     DOI: 10.1038/366707a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  188 in total

Review 1.  Cell cycle checkpoints and their inactivation in human cancer.

Authors:  M Molinari
Journal:  Cell Prolif       Date:  2000-10       Impact factor: 6.831

2.  CAK-independent activation of CDK6 by a viral cyclin.

Authors:  P Kaldis; P M Ojala; L Tong; T P Mäkelä; M J Solomon
Journal:  Mol Biol Cell       Date:  2001-12       Impact factor: 4.138

Review 3.  Cell cycle genes in a mouse mammary hyperplasia model.

Authors:  Thenaa K Said; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

4.  CRL2(LRR-1) targets a CDK inhibitor for cell cycle control in C. elegans and actin-based motility regulation in human cells.

Authors:  Natalia G Starostina; Jennifer M Simpliciano; Michael A McGuirk; Edward T Kipreos
Journal:  Dev Cell       Date:  2010-11-16       Impact factor: 12.270

5.  The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations.

Authors:  Matthew D Westfall; Deborah J Mays; Joseph C Sniezek; Jennifer A Pietenpol
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

6.  Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest.

Authors:  F M Jault; J M Jault; F Ruchti; E A Fortunato; C Clark; J Corbeil; D D Richman; D H Spector
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.

Authors:  C Kunz; S Pebler; J Otte; D von der Ahe
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

8.  Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities.

Authors:  P Kaldis; A A Russo; H S Chou; N P Pavletich; M J Solomon
Journal:  Mol Biol Cell       Date:  1998-09       Impact factor: 4.138

9.  C/EBPα regulates CRL4(Cdt2)-mediated degradation of p21 in response to UVB-induced DNA damage to control the G1/S checkpoint.

Authors:  Jonathan R Hall; Michael S Bereman; Angelito I Nepomuceno; Elizabeth A Thompson; David C Muddiman; Robert C Smart
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  Early events in DNA replication require cyclin E and are blocked by p21CIP1.

Authors:  P K Jackson; S Chevalier; M Philippe; M W Kirschner
Journal:  J Cell Biol       Date:  1995-08       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.